Background Delamanid is one of two recently approved drugs for the treatment of multidrug-resistant
tuberculosis. We aimed to evaluate the safety and efficacy of delamanid in the first …

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is the leading cause of
death from an infectious disease globally. The widespread and ever-increasing resistance to …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) remain
significant global health challenges, with an annual incidence of approximately 480 000 and …

Patients with multidrug-resistant (MDR) tuberculosis (TB), in particular those with pre-extensively
drug-resistant (pre-XDR) and extensively drug-resistant (XDR)-TB, and those that fail …

A population pharmacokinetic analysis of delamanid and its major metabolite DM-6705 was
conducted to characterize the pharmacokinetics of delamanid and DM-6705 in pediatric …

Delamanid has been demonstrated to be safe and effective for treatment of adult multidrug-resistant
tuberculosis (MDR-TB) and has been approved by the European Commission for …

OPC-167832, an inhibitor of decaprenylphosphoryl-β-d-ribose 2’-oxidase, demonstrated
potent antituberculosis activity and a favorable safety profile in preclinical studies. This report …

Pharmacokinetic (PK) and pharmacodynamic (PD) analyses were conducted to determine
the cumulative fraction of response (CFR) for 100 mg twice-daily (BID) and 200 mg once-daily …

Background Although delamanid has been approved for the treatment of multidrug-resistant
TB (MDR-TB) in numerous regions, in areas where it is not yet registered it can be accessed …

Suppression of hepatitis B virus (HBV)‐DNA to undetectable levels is an important goal for
HIV/HBV‐co‐infected patients receiving anti‐HBV‐active antiretroviral therapy (ART), and …